Mylan persuades judge to cut off Glaxo's Paxil copycat; Medicines Patent Pool signs record deal for HIV drug supplies;

@FiercePharma: Tops on FiercePharmaMarketing: Afraid of aging? Pfizer's revamped 'Get old' campaign wants you. Item | Follow @FiercePharma

@TracyStaton: $GSK just can't escape China questions. Ex-workers sue, news of 2001 corruption breaks. More | Follow @TracyStaton

@EricPFierce: Baxter is recalling three lots of saline in the midst of the of the U.S. shortage. FDA recall notice | Follow @EricPFierce

@CarlyHFierce: ICYMI: this week's issue of FiercePharmaMarketing. Report | Follow @CarlyHFierce

> After a years-long court battle, Mylan ($MYL) won an injunction blocking GlaxoSmithKline ($GSK) from supplying copycat versions of its antidepressant Paxil to rival generics maker Apotex. Release

> The Medicines Patent Pool signed 7 new deals with drugmakers to supply cut-rate HIV meds to developing countries. Release

> Baxter ($BAX) pulled in unexpectedly high quarterly earnings on a 16% rise in revenue. More

> French drugmaker Ipsen opened an R&D center in Boston, a move the company hopes will encourage further growth in the U.S. market. Story

> Bayer poached its new U.S. litigation chief, Malini Moorthy, from Pfizer ($PFE), where she served as VP and head of civil litigation. More

> A leading U.S. proxy adviser, ISS, backed Teva's ($TEVA) slate of director nominees and ballot proposals. More

Medical Device News

@FierceMedDev: FDA rejects petition to ban transvaginal mesh. Article | Follow @FierceMedDev

@MichaelGFierce: Delivering breast cancer drug through the skin grants disease prevention. More from FierceDrugDelivery | Follow @MichaelGFierce

@EmilyWFierce: Food resembling human organs was once considered a remedy for disease, but the "Doctrine of Signatures" falls short. Wired story | Follow @EmilyWFierce

> Amid positive Q2 sales, St. Jude looks to renal denervation as untapped niche. Report

> Danaher adds to its diagnostics biz, but deal may not be large enough for the Street. Story

> UPS ramps up delivery service for medical device industry. More

> Medtronic could face legislative pushback in tax-inversion deal with Covidien. Article

Biotech News

@FierceBiotech: Alkermes takes its Tecfidera beater into clinical trials for MS. News | Follow @FierceBiotech

@DamianFierce: Has anyone run the numbers to determine the biggest stock-moving news possible? Cutting jobs + moving to Ireland + buying ultra-rare drug? | Follow @DamianFierce

@EmilyMFierce: 'Biological pacemaker' restores heartbeat in pigs. FierceBiotech Research article | Follow @EmilyMFierce

> Sage up-sizes its ambition on the eve of a much-watched IPO. Story

> Virobay banks $8M to accelerate its treatments for pain, autoimmunity. Article

> Boehringer's lung drug wins FDA 'breakthrough' tag. News

Vaccines News

> Germany's immatics bags $30M for cancer vaccine trial. Article

> Extra dose of inactivated polio vaccine provides greater protection in children. More

> Microbix sues Novartis for patent infringement in Europe. Item

> Novartis' soon-to-be-Glaxo's vax unit sees mounting losses, diving sales in Q2. Story

> As Glaxo begins '14-'15 flu vaccine shipments, manufacturing questions linger. Article

Pharma Manufacturing News

> Aptuit putting $1M into cytotoxic capabilities in Scotland. Item

> GSK recalls acetaminophen products that were not child-proofed. More

> Baxter issues global recall of saline in midst of U.S. shortage. News

> J&J improves McNeil unit sales even as key plant remains closed for remediation. Story

> Pfizer and Sun snatch up sterile injectable companies to boost expertise and capacity. Article

And Finally... Commonly used asthma inhalers that contain steroids can stunt children's growth if dosages aren't carefully monitored, a study found. Story

Suggested Articles

In an era of limited access to key decision makers, how are you mobilizing your field force to communicate the value of your brands and real-world evidence?

Novo Nordisk’s Ozempic is off to a blazing start, and the company just threw more fuel on the fire with a pair of trial wins.

Biosims to Roche's Big 3 cancer drugs will chisel out a $10 billion sales gap by 2023, but newer meds could chip in $16.3 billion, the drugmaker says.